PureTech established the underlying programs and platforms that resulted in 27 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances a third soon filing for FDA approval.
PureTech established the underlying programs and platforms that resulted in 27 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances a third soon filing for FDA approval.

Wholly Owned Pipeline

Our programs1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Idiopathic pulmonary fibrosis (IPF)

2b

IPF

~120K in US

~110K in EU5


Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). Also being advanced under the Animal Rule for radiation induced fibrosis; plans underway to study LYT-100 in progressive fibrosing interstitial lung disease (IPF-ILDs) and exploring LYT-100 in myocardial and other organ system fibrosis.

LYT-200
Anti-Galectin-9 MAb
Solid tumors and hematological malignancies

1/2

Solid tumors

~82K/year U.S. (Bladder cancer)
~66K/year U.S. (Head and neck cancers)
~20K/year U.S. (AML)


Fully human IgG4 monoclonal antibody, or mAb, designed to inhibit the activity of galectin-9, an immunomodulatory molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells. We are developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. We are also developing LYT-200 for the treatment of hematological malignancies, such as acute myeloid leukemia (AML).

LYT-300
Oral Allopregnanolone
Depression, anxiety & related indications

1

Depression, anxiety & related indications

Designed to overcome the poor oral bioavailability of allopregnanolone to advance what we believe could be a best-in-class new medicine for treating anxiety and depression. Allopregnanolone is a positive allosteric modulator of GABAA receptors that has therapeutic potential across a wide range of neurological conditions, including depression and anxiety disorders, though its therapeutic application has been limited due to high first pass metabolism. Our Glyph platform reversibly links a drug to a dietary fat molecule, creating a novel prodrug. We believe this technology has the potential to provide a broadly applicable means of enhancing the bioavailability of certain orally administered drugs that would otherwise be limited by first-pass liver metabolism.

LYT-310
Oral Cannabidiol
Epilepsies & other neurological indications

Preclinical

Epilepsies & other neurological indications

Therapeutic candidate designed to unlock the validated efficacy of cannabidiol (CBD). Derived from the Glyph platform, LYT-310 offers oral dosing and the potential for improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other central nervous system disorders.

Phase completed
Phase in progress
1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication. On July 23, 2021, Imbrium Therapeutics exercised its option to license LYT-503/IMB-150 pursuant to which it is responsible for all future development activities and funding for LYT-503/IMB-150.

Founded Entities

$3.8B2
Investments and Non-Dilutive Funding Raised by Founded Entities Since January 2018 

Advancing transformative medicines for people living with psychiatric and neurological conditions

2.8% Equity plus Milestone Payments/ 20% Sublicense Revenue/ Royalties & up to $500M from agreement w/Royalty Pharma3
PHASE 3

Pioneering the development of cognitive treatments through game-changing technologies

14.6% Equity
COMMERCIAL

Advancing a novel category of treatments for weight management and gut related chronic diseases

22.8% Equity plus Royalties4
COMMERCIAL

Engineering hematopoietic stem cells to enable targeted therapies post-transplant

4.0% Equity
PHASE 1/2a

Pioneering a new category of oral therapies based on defined bacterial consortia

40.8% Equity5
PHASE 3 READY

Developing a voice-based technology platform to detect changes of health conditions

36.5% Equity
COMMERCIAL RELEASE

Engineering hydrogels to enable the oral administration of biologics

73.8% Equity
PRECLINICAL
Note: This figure represents the stage of development for each Founded Entity’s most advanced therapeutic candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities' board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of December 30, 2022, Controlled Founded Entities include Vedanta Biosciences, Inc. and Non-Controlled Founded Entities include Gelesis Holdings, Inc., Karuna Therapeutics, Inc., Akili, Inc., Sonde Health, Inc. and Vor Biopharma Inc. Relevant ownership interests for Founded Entities were calculated on a partially diluted basis (as opposed to a voting basis) as of December 15, 2022, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Gelesis, Vor Bio, Akili and Karuna ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of March 24, 2023, May 5, 2022, May 5, 2023, and April 24, 2023, respectively. With the exception of Plenity® and EndeavorRx®, candidates are investigational and have not been cleared by the FDA for use in the U.S.
2 Funding figure can include private equity financings, loans and promissory notes, public offerings or grant awards, and gross proceeds from SPAC mergers. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations.
3 As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. PureTech retains its equity ownership in Karuna. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.
4 Represents the percentage of Gelesis’ outstanding common stock held by PureTech as of May 12, 2023. On a beneficial ownership basis (as calculated in accordance with SEC rules), PureTech owns 88.4% of the outstanding share capital of Gelesis as of May 26, 2023. On April 27, 2023, PureTech submitted a non-binding proposal to acquire all of the outstanding equity and equity-linked securities of Gelesis. Please see PureTech’s Schedule 13D filings with respect to Gelesis on file with SEC for additional information. PureTech is also eligible to receive certain payments from Gelesis under its license agreement, including sublicense payments and royalties on sales of certain products, including Plenity.
5 As of December 31, 2022, PureTech’s percentage ownership of Vedanta Biosciences was approximately 40.8% on a partially diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans. Vedanta’s $106.5 million recent financing round was structured as convertible debt. PureTech ownership reflects current ownership and does not take into account any potential future dilution, if applicable, as a result of conversion of that debt amount.

Cash at Parent Level

$389.4M
PureTech Level Cash, Cash Equivalents and Short-Term Investments as of March 31, 20238
Operational Runway into Q1 2026
8 This represents a non-IFRS number and is comprised of cash, cash equivalents and short-term investments held at PureTech Health plc and our wholly-owned subsidiaries (PureTech LYT, PureTech LYT-100, Alivio Therapeutics, Inc., PureTech Management, Inc., PureTech Health LLC, PureTech Securities Corp, PureTech Securities II) as of March 31, 2023. Please see above for a reconciliation of this measure to consolidated cash, cash equivalents and short-term investments, which is the most directly comparable measure calculated in accordance with IFRS

Developing breakthrough medicines at PureTech

Relationships with leading pharma companies or their investment arms

Relationships with leading pharma companies or their investment arms